Aethon Therapeutics

About

Aethon Therapeutics is a biotechnology company based in New York, dedicated to developing innovative antibody therapeutics that integrate immunotherapy and targeted therapy to effectively target cancer cells, including those resistant to existing treatments. The company utilizes its proprietary HapImmune™ platform to create neoantigens, aiming to transform cancer treatments into potential cures. Aethon focuses on engineering custom anti-drug-peptide conjugate/MHC antibodies that work alongside targeted covalent inhibitors to address oncogenic drivers such as RAS, EGFR, and BTK. Their approach targets mitochondrial metabolism, which is essential for cancer cell survival, by activating immune responses against inhibitor-bound cancer cells. The company is advancing several preclinical candidates, including bispecific antibodies and covalent inhibitors aimed at generating cancer-specific neoantigens. Aethon has established a partnership with Revolution Medicines to develop bispecific antibodies for RAS-addicted cancers, further enhancing its research and development efforts. The company is also a member of NewYorkBIO.